l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. [MeSH]
*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. [MeSH]
| Studies (l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine) | Trials (l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine) | Recent Studies (post-2010) (l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine) | Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 3,859 | 8 | 1,052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ | 1 |
1 other study(ies) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors | 1989 |